Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

19 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

perampanel Articles

Eisai's Fycompa improves seizure control, pivotal Ph III study shows

27 July 2012

US FDA delays Eisai's Dacogen for AML; accepts perampanel NDA

8 March 2012

Eisai re-submits perampanel NDA; FDA accepts Gilead’s Quad

28 December 2011

Eisai updates on epilepsy drugs Zonegran, Zebinix and perampanel at IEC

31 August 2011

Eisai epilepsy drug delayed by US FDA, but Zonegran use extension filing accepted in EU

1 August 2011

Eisai Ph III study for eritoran fails to meet primary endpoint, but perampanel filing due this quarter

26 January 2011

Eisai reports positive Ph III results for perampanel in partial epilepsy

25 August 2010

Showing 1-7 of 7 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Neovacs moving forward in rheumatoid arthritis, say analysts
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Neovacs moving forward in rheumatoid arthritis, say analysts

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS